Literature DB >> 24329492

Androgen receptor inducing bladder cancer progression by promoting an epithelial-mesenchymal transition.

W Jitao1, H Jinchen, L Qingzuo, C Li, S Lei, W Jianming, G Zhenli.   

Abstract

The study investigated the role of androgen receptor (AR) as a potential target for the treatment of bladder cancer in regulating epithelial-mesenchymal transition or transformation (EMT). Cell proliferation, and migration capacity were determined in bladder cancer T24 cells treated with small interfering RNA directed against AR, and expression levels of E-cadherin, β-catenin and N- cadherin were assessed using quantitative reverse transcription PCR (qRT-PCR). Tumour cell growth was evaluated in vivo in T24 tumour-bearing nude mice receiving electroporation-assisted administration of anti-AR small interfering RNA. It was found that low AR expression decreased proliferation and migration of bladder cancer cells. In vivo experiments showed that silencing AR expression significantly suppressed AR-positive bladder tumour growth with decreased cell proliferation. Low AR level of T24 bladder cancer cells treated with dehydrotestosterone (DHT) decreased expression of E-cadherin, β-catenin and N-cadherin expression, indicating a strong sensitivity to the EMT and In cells with low AR content, TGF-β induced down-regulation of E-cadherin and β-catenin. It is concluded that suppression of AR expression decreased the production of TGF-β, inhibiting EMT and bladder cancer cell growth in vitro and in vivo, implying that its use might be a potential therapeutic target for the treatment of bladder cancer.
© 2013 Blackwell Verlag GmbH.

Entities:  

Keywords:  Androgen receptor; bladder cancer; epithelial; mesenchymal transition

Mesh:

Substances:

Year:  2013        PMID: 24329492     DOI: 10.1111/and.12203

Source DB:  PubMed          Journal:  Andrologia        ISSN: 0303-4569            Impact factor:   2.775


  7 in total

Review 1.  Targeted therapies in bladder cancer: an overview of in vivo research.

Authors:  Kim E M van Kessel; Tahlita C M Zuiverloon; Arnout R Alberts; Joost L Boormans; Ellen C Zwarthoff
Journal:  Nat Rev Urol       Date:  2015-09-22       Impact factor: 14.432

2.  Infiltrating T Cells Promote Bladder Cancer Progression via Increasing IL1→Androgen Receptor→HIF1α→VEGFa Signals.

Authors:  Le Tao; Jianxin Qiu; Ming Jiang; Wenbin Song; Shuyuan Yeh; Hong Yu; Lijuan Zang; Shujie Xia; Chawnshang Chang
Journal:  Mol Cancer Ther       Date:  2016-05-11       Impact factor: 6.261

Review 3.  Androgen Receptor Signaling in Bladder Cancer.

Authors:  Peng Li; Jinbo Chen; Hiroshi Miyamoto
Journal:  Cancers (Basel)       Date:  2017-02-22       Impact factor: 6.639

4.  Dihydrotestosterone increases the risk of bladder cancer in men.

Authors:  Dorota Gil; Marta Zarzycka; Joanna Dulińska-Litewka; Dorota Ciołczyk-Wierzbicka; Małgorzata Lekka; Piotr Laidler
Journal:  Hum Cell       Date:  2019-05-22       Impact factor: 4.174

Review 5.  Involvement of the Androgen and Glucocorticoid Receptors in Bladder Cancer.

Authors:  Lucien McBeth; Maria Grabnar; Steven Selman; Terry D Hinds
Journal:  Int J Endocrinol       Date:  2015-08-10       Impact factor: 3.257

6.  Effects of increased Kindlin-2 expression in bladder cancer stromal fibroblasts.

Authors:  Jitao Wu; Cuicui Yu; Li Cai; Youyi Lu; Lei Jiang; Chu Liu; Yongwei Li; Fan Feng; Zhenli Gao; Zhe Zhu; Shengqiang Yu; Hejia Yuan; Yuanshan Cui
Journal:  Oncotarget       Date:  2017-04-10

7.  Androgen receptor signalling confers clonogenic and migratory advantages in urothelial cell carcinoma of the bladder.

Authors:  Maria V Luna-Velez; Jelmer J Dijkstra; Marina A Heuschkel; Frank P Smit; Guillaume van de Zande; Dominique Smeets; J P Michiel Sedelaar; Michiel Vermeulen; Gerald W Verhaegh; Jack A Schalken
Journal:  Mol Oncol       Date:  2021-05-22       Impact factor: 6.603

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.